The story of Sildenafil presents a complex case for investors in the pharmaceutical sector. While initially a blockbuster success, generating huge profits, the intellectual property lapse and the subsequent flood of cheaper competitors have significantly changed income. This poses questions about the long-term profitability of similar therapeutic i